Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions
Treatment of brain cancers, especially high grade gliomas (WHO stage III and IV) is slowly making progress, but not as fast as medical researchers and the patients would like. Immunotherapy offers the opportunity to allow the patient's own immune system a chance to help eliminate the cancer. Im...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2010/296453 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562133229895680 |
|---|---|
| author | Lisheng Ge Neil Hoa Daniela A. Bota Josephine Natividad Andrew Howat Martin R. Jadus |
| author_facet | Lisheng Ge Neil Hoa Daniela A. Bota Josephine Natividad Andrew Howat Martin R. Jadus |
| author_sort | Lisheng Ge |
| collection | DOAJ |
| description | Treatment of brain cancers, especially high grade gliomas (WHO stage III and IV) is slowly making progress, but not as fast as medical researchers and the patients would like. Immunotherapy offers the opportunity to allow the patient's own immune system a chance to help eliminate the cancer. Immunotherapy's strength is that it efficiently treats relatively small tumors in experimental animal models. For some patients, immunotherapy has worked for them while not showing long-term toxicity. In this paper, we will trace the history of immunotherapy for brain cancers. We will also highlight some of the possible directions that this field may be taking in the immediate future for improving this therapeutic option. |
| format | Article |
| id | doaj-art-d8472d953e6845c2a0697cca72b35831 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-d8472d953e6845c2a0697cca72b358312025-02-03T01:23:21ZengWileyClinical and Developmental Immunology1740-25221740-25302010-01-01201010.1155/2010/296453296453Immunotherapy of Brain Cancers: The Past, the Present, and Future DirectionsLisheng Ge0Neil Hoa1Daniela A. Bota2Josephine Natividad3Andrew Howat4Martin R. Jadus5Pathology and Laboratory Medicine Service, Department of Diagnostic and Molecular Medicine Health Care Group, VA Long Beach Healthcare System, 5901 E. 7th Street, Long Beach, CA 90822, USAPathology and Laboratory Medicine Service, Department of Diagnostic and Molecular Medicine Health Care Group, VA Long Beach Healthcare System, 5901 E. 7th Street, Long Beach, CA 90822, USADepartment of Neurology and Department of Neurological Surgery, Chao Family Comprehensive Cancer Center, UC Irvine School of Medicine, University of California, Irvine, CA 92697, USAPathology and Laboratory Medicine Service, Department of Diagnostic and Molecular Medicine Health Care Group, VA Long Beach Healthcare System, 5901 E. 7th Street, Long Beach, CA 90822, USAPathology and Laboratory Medicine Service, Department of Diagnostic and Molecular Medicine Health Care Group, VA Long Beach Healthcare System, 5901 E. 7th Street, Long Beach, CA 90822, USAPathology and Laboratory Medicine Service, Department of Diagnostic and Molecular Medicine Health Care Group, VA Long Beach Healthcare System, 5901 E. 7th Street, Long Beach, CA 90822, USATreatment of brain cancers, especially high grade gliomas (WHO stage III and IV) is slowly making progress, but not as fast as medical researchers and the patients would like. Immunotherapy offers the opportunity to allow the patient's own immune system a chance to help eliminate the cancer. Immunotherapy's strength is that it efficiently treats relatively small tumors in experimental animal models. For some patients, immunotherapy has worked for them while not showing long-term toxicity. In this paper, we will trace the history of immunotherapy for brain cancers. We will also highlight some of the possible directions that this field may be taking in the immediate future for improving this therapeutic option.http://dx.doi.org/10.1155/2010/296453 |
| spellingShingle | Lisheng Ge Neil Hoa Daniela A. Bota Josephine Natividad Andrew Howat Martin R. Jadus Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions Clinical and Developmental Immunology |
| title | Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions |
| title_full | Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions |
| title_fullStr | Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions |
| title_full_unstemmed | Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions |
| title_short | Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions |
| title_sort | immunotherapy of brain cancers the past the present and future directions |
| url | http://dx.doi.org/10.1155/2010/296453 |
| work_keys_str_mv | AT lishengge immunotherapyofbraincancersthepastthepresentandfuturedirections AT neilhoa immunotherapyofbraincancersthepastthepresentandfuturedirections AT danielaabota immunotherapyofbraincancersthepastthepresentandfuturedirections AT josephinenatividad immunotherapyofbraincancersthepastthepresentandfuturedirections AT andrewhowat immunotherapyofbraincancersthepastthepresentandfuturedirections AT martinrjadus immunotherapyofbraincancersthepastthepresentandfuturedirections |